Jiangsu Aidea Pharmaceutical Co., Ltd. (688488.SS)
CNY 8.87
(2.31%)
CNY 8.87
(2.31%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 411.32 Million CNY | 68.43% |
| 2022 | 244.21 Million CNY | -4.49% |
| 2021 | 255.7 Million CNY | -11.54% |
| 2020 | 289.05 Million CNY | -16.27% |
| 2019 | 345.22 Million CNY | 24.67% |
| 2018 | 276.9 Million CNY | 103.21% |
| 2017 | 136.26 Million CNY | -47.15% |
| 2016 | 257.84 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 91.97 Million CNY | -16.24% |
| 2024 Q2 | 87.13 Million CNY | -5.26% |
| 2024 Q3 | 116 Million CNY | 35.2% |
| 2023 Q2 | 126.11 Million CNY | 11.99% |
| 2023 FY | 411.32 Million CNY | 68.43% |
| 2023 Q4 | 109.8 Million CNY | 74.81% |
| 2023 Q3 | 62.81 Million CNY | -50.19% |
| 2023 Q1 | 112.62 Million CNY | 2.25% |
| 2022 Q3 | 60.3 Million CNY | 55.91% |
| 2022 FY | 244.21 Million CNY | -4.49% |
| 2022 Q2 | 38.67 Million CNY | 10.19% |
| 2022 Q1 | 35.1 Million CNY | -23.86% |
| 2022 Q4 | 110.13 Million CNY | 82.65% |
| 2021 Q2 | 79.06 Million CNY | 1.44% |
| 2021 Q1 | 77.94 Million CNY | -21.39% |
| 2021 Q4 | 46.1 Million CNY | -12.36% |
| 2021 Q3 | 52.6 Million CNY | -33.47% |
| 2021 FY | 255.7 Million CNY | -11.54% |
| 2020 Q2 | 84.05 Million CNY | 88.22% |
| 2020 Q1 | 44.65 Million CNY | -67.48% |
| 2020 FY | 289.05 Million CNY | -16.27% |
| 2020 Q4 | 99.14 Million CNY | 62.02% |
| 2020 Q3 | 61.19 Million CNY | -27.2% |
| 2019 Q4 | 137.32 Million CNY | 204.56% |
| 2019 Q2 | 82.34 Million CNY | 2.34% |
| 2019 Q1 | 80.46 Million CNY | 0.0% |
| 2019 FY | 345.22 Million CNY | 24.67% |
| 2019 Q3 | 45.09 Million CNY | -45.24% |
| 2018 FY | 276.9 Million CNY | 103.21% |
| 2017 FY | 136.26 Million CNY | -47.15% |
| 2016 FY | 257.84 Million CNY | 0.0% |